Genelux Corporation (GNLX) Stock Ticker
GNLX right now
Market factors today
Unlock the full GNLX picture
About Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX stock facts
| Ticker symbol | GNLX |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $111.2M |
| CEO | Thomas D. Zindrick |
| Employees | 26 |
| Headquarters | Westlake Village, CA, US |
| IPO date | 2023-01-26 |
| Website | www.genelux.com |
What you can see for GNLX on Tickr
Live GNLX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GNLX report.
Rankings
FAQ
What is the ticker symbol for Genelux Corporation?
The ticker symbol for Genelux Corporation is GNLX, listed on the NASDAQ Global Market.
What is GNLX?
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also…